NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Amersham Biosciences 

800 Centennial Avenue

Piscataway  New Jersey  08855  U.S.A.
Phone: 732-457-8000 Fax: 732-457-0557


SEARCH JOBS
Amersham Biosciences (formerly Amersham Pharmacia Biotech) is at the forefront of drug discovery providing the technologies to uncover, develop and produce molecular medicines faster and more cost-effectively than ever before. Focusing on the importance of functional biology, the company is a world leader in developing and providing integrated technology platforms that provide innovative and sophisticated solutions for genomic and proteomic research, drug discovery and development and biopharmaceutical manufacturing, that combine informatics, instrumentation, reagents and service to ensure maximum productivity. Amersham Biosciences, the life sciences business of Amersham plc (LSE, NYSE, OSE: AHM), is an international leader in the markets of genomics, proteomics, bioassays, separations and bioinformatics. The customer base for Amersham Biosciences' products and technologies are pharmaceutical and biotechnology companies, leading research and academic institutions in the United States, Europe, Latin America and Asia.

In 2001, Amersham Biosciences spent 12.6 percent of its revenue on research and development. It is this commitment to R&D that underpins the company's successful track record in developing key technologies in the life sciences. These include: MegaBACE?, the automated high-throughput DNA analysis system; LEADseeker?, the homogenous imaging system for high-throughput screening of new potential drugs; KTA? design chromatography systems, used for purification of proteins; and Streamline?, Source? and Chromaflow? for the production of protein-based biopharmaceutical medications.

Amersham Biosciences is an innovative leader in microarrays and proteomics, two critical areas bridging the gap between draft maps of the human genome and the eventual development of personalized medicine to help improve human health.

Headquartered in Piscataway, New Jersey, Amersham Biosciences operates globally with more than 90 full service sales offices as well as major research and development and production sites in Piscataway, New Jersey; San Francisco and Sunnyvale, California; Uppsala, Sweden; Tokyo, Japan and Amersham and Cardiff, UK.

For more information about Amersham Biosciences, please visit our website at www.amershambiosciences.com.

Last Updated: 02-07-05


 Key Statistics


Email:
Ownership:
Web Site: Amersham Biosciences
Employees: Around 4,000 employees worldwide in 30 countries
Symbol: 
 





Collaborations

V.I. Technologies, Inc. (VITEX) 

Pharmagene Laboratories Limited 

Bristol-Myers Squibb Company 

Johnson & Johnson 

Beckman Coulter, Inc.  Partnership to improve capillary electrophoresis technology.

Praelux Incorporated  Acquired February 2000; secondary drug screening research.

SNP Consortium  A two-year, $53 million, not-for-profit initiative to identify and analyze genetic markers.

Imaging Research, Inc. (Canada)  Development of advanced imaging instrumentation and analysis software for drug screening.

CanadaBioMolecular Technologies, Inc.  Development of automated protein analysis systems.

Intergen Company 





 Company News
ONCURA Confirms That They Will Not Renew US Distribution Agreement With Theragenics Corporation (TGX) When It Expires In December 2005 10/19/2005 5:12:26 PM    More...
The European Collaborative Group On Prostate Brachytherapy Reports On Over 1,150 Patients Treated With ONCURA's RAPID Strand(TM) 10/19/2005 5:12:17 PM    More...
BioInformatics LLC Release: Announcing The 2004 Life Science Industry Award Finalists 10/19/2005 5:12:13 PM    More...
GE Completes Acquisition Of Amersham PLC; Transaction Will Shape A New Age In Patient Care 10/19/2005 5:10:50 PM    More...
Amersham Biosciences Updates CodeLink Informatics Solution To Provide Complete Data Management 10/19/2005 5:10:49 PM    More...
Amersham plc Appoints Peter Loescher As Chief Operating Officer 10/19/2005 5:10:45 PM    More...
Acquisition Of Amersham PLC - Exchange Ratio 10/19/2005 5:10:43 PM    More...
Amersham Biosciences Advances Analysis Of Gene Expression With New CodeLink Human Whole Genome Bioarray 10/19/2005 5:10:42 PM    More...
Amersham Biosciences: New Study Reveals Significant Differences In Protein Expression Between Normal And Colorectal Cancer Samples Using Ettan DIGE Technology 10/19/2005 5:10:33 PM    More...
Eli Lilly and Company (LLY) Complements Its Drug Discovery Research With Integrated Cellular Screening System From Amersham Biosciences 10/19/2005 5:10:22 PM    More...
123